BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Instabase Becomes SuperApp, Launches the AI Collaboration Super App17.8.2026 12:00:00 CEST | Press release
AI was single-player. SuperApp makes it multiplayer Your whole team and leading AI models from Anthropic, OpenAI, Google, xAI, and others think, debate, and create together in one live thread — from the first idea to the final deliverable. Available today. SuperApp, Inc., formerly Instabase, Inc., today launched SuperApp, the AI collaboration super app, available on the web, iOS, Android, and desktop. SuperApp brings teams and leading AI models from Anthropic, OpenAI, Google, xAI, and others into one live thread — from the first conversation to finished work. The company changed its name to reflect the new product and company direction. Work today is split into three. Teams talk in one app. They ask AI in another. They make the final work somewhere else. Every handoff asks people to remember what the software forgot. SuperApp brings those moments together. People and AI begin in the same live thread. Teams can use Claude from Anthropic, GPT from OpenAI, Gemini from Google, Grok from xA
Confluence Launches Confluence POINT, Bringing AI-Enabled Automation Across Its Product Suite.17.8.2026 11:04:00 CEST | Press release
Document validation and intelligence and the Revolution conversational interface are live today; the first in a wave of AI capabilities running within and alongside Confluence’s solutions. Confluence Technologies, Inc. (“Confluence”), a global leader in regulatory, analytics, and investor communications solutions for the investment management industry, today announced the launch of Confluence POINT, AI-enabled automation that optimizes workflows across its solutions. Confluence delivers specialist regulatory, analytics and investor solutions that are unrivalled at what they do. POINT is AI-enabled automation that runs within and alongside these solutions, letting them do more for our clients, reducing manual effort that typically occurs before or after automated processes. POINT Validation transforms and validates documents across a range of formats, including unstructured data. POINT’s AI-powered validation is complete in minutes, delivered via an automated checklist that runs indepen
Xsolla Adds 15+ New Local Payment Methods, Letting Game Developers Reach Players Across Asia-Pacific, Europe, and the Americas17.8.2026 10:00:00 CEST | Press release
Now Live: Mandiri, ShopeePay, LINE Pay, Octopus, Konbini 7/11, China UnionPay, Zip Co, Wero, Pay by Bank, FLOA Pay BNPL, Bancomat Pay, MyBank, IRIS Commerce, CliQ, and Aeropay Xsolla, a global video game commerce company, today announced the addition of 15+ new payment methods to Xsolla Payments ahead of Gamescom 2026, spanning Asia and Oceania, EMEA, and the Americas. Game developers and publishers can now accept the local payment methods players already use, across markets from Indonesia and the Philippines to Germany, France, and the United States, with no additional integration required for any individual method. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817000143/en/ Graphic: Xsolla The shift toward local payment methods is reshaping the digital payments landscape well beyond emerging markets. Across Europe, banks and regulators are building account-to-account and instant-payment alternatives to international ca
SES Expands into Global Direct-to-Device Services through Strategic Collaboration with Elveo Mobile17.8.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, today announced an expanded strategic investment and collaboration with Elveo Mobile (Elveo), the new company created through the completion of the Lynk and Omnispace merger. Elveo unites the heritage of two pioneers in direct-to-device (D2D) services and will deliver mobile connectivity from space to mobile phones, devices and machines around the world. SES will support Elveo in accelerating its delivery of powerful, cost-effective global D2D services. SES and Elveo will also work together on global spectrum initiatives that will enable Elveo to unlock delivery of D2D solutions. By partnering with Elveo, SES deepens its commitment with access to its expansive, global space and ground infrastructure, while also supporting Elveo's go-to-market, engineering, operations and regulatory needs. The collaboration will enable SES to enhance current services for its mobile telecom, enterprise, and government customers around the world. SES users will ben
Trading Central Launches a UCITS ETF17.8.2026 09:30:00 CEST | Press release
Trading Central SA (“Trading Central”) announces the launch of a UCITS European Quant ETF in partnership with HANetf Asset Management, one of Europe’s leading white-label UCITS ETF and ETC platforms. The following ETF is now trading on Euronext Paris (eligible to PEA), Milan, Dublin, and Börse Frankfurt, and is coming soon to more European stock exchanges and in currencies besides the Euro. Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This release marks Trading Central’s continued expansion into investable products, supporting self-directed retail clients with its award-winning, proprietary financial research and data. “For years, Trading Central has helped investors make more informed decisions through independent research and analytics,” said Alain Pellier, CEO of Trading Central SA. “The introduction of our TC Quant ETF is a natural next step in our mission—o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom